When Will Generic Ozempic
Be Available in the UK?

Understanding drug patents and exclusivity

When a pharmaceutical company develops a new medicine, it is granted patents that protect its investment by preventing other companies from manufacturing and selling copies. In the United Kingdom, drug patents typically last 20 years from the filing date. However, because it takes many years to develop a drug and obtain regulatory approval, much of the patent term is consumed before the product reaches the market.

To compensate for this, European and UK law allows for supplementary protection certificates (SPCs), which can extend effective patent protection by up to five years beyond the base patent expiry. In practice, this means a successful medicine may have market exclusivity for 10 to 15 years from the date it is first approved.

Types of patent protection

• Compound patent: Protects the active substance itself (semaglutide). This is the broadest and most fundamental patent.
• Formulation patents: Protect specific delivery forms, such as the injectable pen device or the oral tablet formulation.
• Method-of-use patents: Protect specific therapeutic indications, such as weight management or type 2 diabetes.
• Manufacturing process patents: Protect the specific methods used to produce the drug at scale.

Semaglutide patent timeline

Ozempic (semaglutide 0.25 mg, 0.5 mg and 1 mg) was first approved by the European Medicines Agency in 2018 for type 2 diabetes. Wegovy (semaglutide 2.4 mg) was approved for weight management in 2022. The patent landscape for semaglutide is complex because Novo Nordisk holds multiple overlapping patents.

Biosimilars versus generics: why it matters

Semaglutide is a GLP-1 receptor agonist peptide — a large, complex biological molecule produced through biotechnology rather than traditional chemical synthesis. This classification has significant implications for how copies can be made and approved.

Small-molecule generics

For simple chemical drugs like paracetamol or metformin, a generic manufacturer can demonstrate that its product is chemically identical to the original (bioequivalence). This process is relatively straightforward and inexpensive, which is why generic tablets are often 80 to 90 per cent cheaper than branded versions.

Biosimilars for biologics

For biological medicines like semaglutide, exact replication is not possible because the molecules are produced by living cells and have inherent variability. Instead, manufacturers develop biosimilars — products that are highly similar to the reference biologic with no clinically meaningful differences in safety, purity or potency.

Biosimilar development requires:

• Extensive analytical characterisation comparing the biosimilar to the reference product
• Preclinical studies (laboratory and animal testing)
• At least one clinical trial demonstrating equivalent efficacy and safety
• A dedicated pharmacovigilance plan for post-marketing surveillance

This process typically takes five to eight years and costs between 100 and 300 million US dollars, compared with two to five million for a traditional generic. As a result, biosimilars offer more modest price reductions than generic tablets.

Who is developing biosimilar semaglutide?

Several pharmaceutical and biotechnology companies have announced biosimilar semaglutide development programmes. While specific UK launch dates cannot be confirmed at this stage, the competitive interest suggests that biosimilar semaglutide will eventually become available.

Companies that have publicly disclosed semaglutide biosimilar programmes include major Indian generic manufacturers, established European biosimilar developers and several Chinese biotechnology firms. The exact number of programmes and their stages of development are evolving rapidly.

It is worth noting that Novo Nordisk itself may respond to biosimilar competition by launching an authorised generic or reducing the price of branded Ozempic, as has occurred with other biologics facing biosimilar entry.

What will biosimilar semaglutide cost?

The current NHS list price for Ozempic is approximately 70 to 75 pounds per month for the 1 mg dose. The private market price for weight management is considerably higher, typically 150 to 300 pounds per month depending on the clinic and dose.

Expected price reductions

• First biosimilar entry: Typically 20 to 30 per cent below the originator price
• Multiple biosimilars on market: Prices may fall 40 to 60 per cent below the original branded product
• Long-term: In the insulin market, biosimilar competition has reduced prices by up to 70 per cent in some European countries

MHRA approval pathway for biosimilars

In the United Kingdom, biosimilars are assessed by the Medicines and Healthcare products Regulatory Agency (MHRA). Since Brexit, the MHRA has operated an independent regulatory pathway, although it may still consider evidence from European Medicines Agency (EMA) assessments.

The MHRA biosimilar approval process requires:

1. A comprehensive quality dossier demonstrating high similarity to the reference product
2. Non-clinical studies comparing the biosimilar and reference product
3. At least one comparative clinical study (typically a randomised controlled trial)
4. A risk management plan and pharmacovigilance strategy

The review process typically takes 12 to 18 months from submission to decision. The MHRA has approved numerous biosimilars for other biologics, including adalimumab, infliximab and several insulin products.

The compounded semaglutide problem

The high demand for semaglutide and current supply constraints have led to a proliferation of compounded semaglutide products, particularly in the United States. Some of these products have found their way to UK consumers through online channels.

Key risks of compounded or unregulated semaglutide include:

• Dosing inaccuracy: Without standardised manufacturing, the actual dose may differ from what is labelled
• Contamination: Non-sterile preparation can introduce bacteria or particulate matter
• Stability issues: Without proper stability testing, the product may degrade before its labelled expiry date
• No regulatory oversight: No post-marketing surveillance to detect safety signals
• Legal risk: Importing unlicensed medicines into the UK may be illegal

What this means for NHS patients

For patients currently prescribed semaglutide through the NHS or private clinics, the introduction of biosimilars will bring several potential benefits.

Improved access

Lower costs would allow the NHS to treat more patients with semaglutide. Currently, NICE guidance restricts Wegovy prescribing through specialist weight management services, partly because of cost considerations. Cheaper biosimilar versions could make semaglutide available to a wider population, including through primary care.

Switching from branded to biosimilar

Based on experience with other biosimilars on the NHS, patients currently taking branded Ozempic or Wegovy may be switched to a biosimilar once one becomes available. The MHRA and NICE have established frameworks for biosimilar switching that prioritise patient safety and informed consent.

Evidence from other therapeutic areas shows that switching from an originator biologic to a biosimilar is safe and does not result in loss of efficacy. The NHS has successfully transitioned large numbers of patients from branded to biosimilar adalimumab, infliximab and insulin products.

Private prescribing

Patients who pay privately for semaglutide through online weight loss clinics or high street clinics should see the most significant price reductions. Competition from biosimilars would reduce the wholesale cost, which private prescribers typically pass on to patients.

Timeline: when to expect biosimilar semaglutide in the UK

Based on current patent protection, biosimilar development timelines and MHRA review processes, a realistic timeline for biosimilar semaglutide availability in the UK is:

• 2026 to 2028: Biosimilar development programmes completing clinical trials
• 2029 to 2031: First biosimilar submissions to the MHRA (depending on SPC and formulation patent outcomes)
• 2031 to 2033: First biosimilar semaglutide potentially available on the UK market
• 2033 onwards: Multiple biosimilars competing, driving further price reductions

This timeline could be accelerated if patent challenges succeed or if Novo Nordisk's SPCs are not upheld. Conversely, it could be delayed if the company successfully defends its formulation patents through litigation.

Frequently asked questions